Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
RSV, Merck
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants. The seasonal shot met its primary goal in the mid-to-late stage trial,
1d
on MSN
Merck lowers mid-term healthcare outlook after recent drug failures
German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, ...
14h
Merck KGaA Boss Is Scoffing at the Obesity Hype: Leader Q&A
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Business Wire
22h
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease …
Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...
BioSpace
7h
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
FierceBiotech
1d
With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
10d
on MSN
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive ...
FiercePharma
10d
Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...
11d
Merck Is At Support And Should Go Higher (Technical Analysis)
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...
22h
Merck's Clesrovimab Lowers RSV Disease And Hospitalization In Preterm And Full-term Infants
Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback